Document Detail

Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane.
MedLine Citation:
PMID:  20331609     Owner:  NLM     Status:  MEDLINE    
Cell expansion and metastasis are considered hallmarks of tumour progression. Therefore, efforts have been made to develop novel anti-cancer drugs that inhibit both the proliferation and the motility of tumour cells. Synthetic alkylphospholipids, compounds with aliphatic side chains that are ether linked to a glycerol backbone, are structurally derived from platelet-activating factor and represent a new class of drugs with anti-proliferative properties in tumour cells. These compounds do not interfere with the DNA or mitotic spindle apparatus of the cell. Instead, they are incorporated into cell membranes, where they accumulate and interfere with lipid metabolism and lipid-dependent signalling pathways. Recently, it has been shown that the most commonly studied alkylphospholipids inhibit proliferation by inducing apoptosis in malignant cells while leaving normal cells unaffected. This review focuses on a novel group of synthetic alkylphospholipids, the glycosidated phospholipids, which contain carbohydrates or carbohydrate-related molecules at the sn-2 position of the glycerol backbone. Members of this subfamily also exhibit anti-proliferative capacity and modulate the cell adhesion, differentiation, and migration of tumour cells. Among this group, Ino-C2-PAF shows the highest efficacy and low cytotoxicity. Apart from its anti-proliferative effect, Ino-C2-PAF strongly reduces cell motility via its inhibitory effect on the phosphorylation of the cytosolic tyrosine kinases FAK and Src. Signalling pathways under the control of the FAK/Src complex are normally required for both migration and proliferation and play a prominent role in tumour progression. We intend to highlight the potential of glycosidated phospholipids, especially Ino-C2-PAF, as a promising new group of drugs for the treatment of hyperproliferative and migration-based skin diseases.
Kerstin Danker; Werner Reutter; Geo Semini
Related Documents :
1422189 - A possible role for cysteine proteinase and its inhibitors in motility of malignant mel...
1669439 - Temporary competitive inhibition of a tumour cell surface protease as a protective mech...
914009 - Cytoenzymology of benign and malignant tumours of the corpus uteri. iii. alkaline phosp...
17250959 - Variation, "evolution", immortality and genetic instabilities in tumour cells.
7903289 - Cell proliferation in breast tumours: analysis of histological parameters ki67 and pcna...
12020799 - Src in cancer: deregulation and consequences for cell behaviour.
17686159 - Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant m...
16755039 - Efficient gene transfer into differentiated human trophoblast cells with adenovirus vec...
23261449 - Rheological responses of cardiac fibroblasts to mechanical stretch.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-03-19
Journal Detail:
Title:  British journal of pharmacology     Volume:  160     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-23     Completed Date:  2010-07-26     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  36-47     Citation Subset:  IM    
Charité-Universitaetsmedizin Berlin, Campus Mitte, Institut fuer Biochemie, Monbijoustr, Berlin.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  pharmacology*
Cell Membrane / metabolism
Cell Movement / drug effects
Cell Proliferation / drug effects
Glycosides / adverse effects,  pharmacology*
Inositol / adverse effects,  analogs & derivatives,  pharmacology
Molecular Structure
Neoplasm Metastasis
Neoplasms / drug therapy,  pathology
Phospholipids / adverse effects,  pharmacology*
Platelet Activating Factor / adverse effects,  analogs & derivatives,  pharmacology
Signal Transduction
Reg. No./Substance:
0/Antineoplastic Agents; 0/Glycosides; 0/Phospholipids; 0/Platelet Activating Factor; 6917-35-7/Inositol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Headache-type adverse effects of NO donors: vasodilation and beyond.
Next Document:  Expression patterns and association analysis of the porcine DHX58 gene.